Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NUC B1000
- Development stage
- Discontinued
- Lead developer
- Nucleonics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
NUC B1000 is an expressed interfering RNA (eiRNA)-based therapeutic developed by Nucleonics, Inc. for the treatment of chronic hepatitis B virus (HBV) infection. The drug consists of a plasmid DNA construct designed to produce four distinct short interfering RNA (siRNA) molecules, formulated within a proprietary cationic-lipid delivery system. Each of the four siRNAs targets a different conserved sequence of the HBV genome, collectively designed to degrade all viral RNA species produced within infected cells. This multi-target approach aims to prevent viral escape and effectively inhibit HBV replication and protein expression. NUC B1000 entered Phase I clinical testing in 2008 to evaluate safety and tolerability in patients with chronic HBV, but development was subsequently discontinued following the closure of Nucleonics.
- Other names
- NUC-B1000NUC-B-1000NUC-B 1000
Beyond the preview
Go deeper on NUC B1000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NUC B1000.